Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M131,312Revenue $M39,553Net Margin (%)13.3Altman Z-Score2.4
Enterprise Value $M142,139EPS $2.0Operating Margin %18.9Piotroski F-Score5
P/E(ttm)24.5Beneish M-Score-2.4Pre-tax Margin (%)17.5Higher ROA y-yY
Price/Book2.010-y EBITDA Growth Rate %2.7Quick Ratio0.9Cash flow > EarningsN
Price/Sales3.25-y EBITDA Growth Rate %-2.9Current Ratio1.4Lower Leverage y-yN
Price/Free Cash Flow48.2y-y EBITDA Growth Rate %8.7ROA % (ttm)8.5Higher Current Ratio y-yN
Dividend Yield %3.2PEG--ROE % (ttm)14.8Less Shares Outstanding y-yN
Payout Ratio %79.0Shares Outstanding M2,622ROIC % (ttm)14.3Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYNWQ Managers 2015-06-30 Reduce-0.8%$48.81 - $52.35
($50.66)
$ 50.08-1%Reduce 32.87%2,636,361
SNYDodge & Cox 2015-06-30 Add0.3%$48.81 - $52.35
($50.66)
$ 50.08-1%Add 15.64%49,765,693
SNYHOTCHKIS & WILEY 2015-06-30 Reduce-0.19%$48.81 - $52.35
($50.66)
$ 50.08-1%Reduce 9.17%10,701,542
SNYJames Barrow 2015-06-30 Reduce-0.02%$48.81 - $52.35
($50.66)
$ 50.08-1%Reduce 0.87%29,961,207
SNYKen Fisher 2015-06-30 Add0.02%$48.81 - $52.35
($50.66)
$ 50.08-1%Add 1.44%13,246,593
SNYCharles Brandes 2015-06-30 Reduce-0.01%$48.81 - $52.35
($50.66)
$ 50.08-1%Reduce 0.52%2,560,460
SNYNWQ Managers 2015-03-31 Add0.61%$44 - $51.12
($47.81)
$ 50.085%Add 33.50%3,927,517
SNYJames Barrow 2015-03-31 Reduce-0.04%$44 - $51.12
($47.81)
$ 50.085%Reduce 1.88%30,225,221
SNYHOTCHKIS & WILEY 2015-03-31 Add0.02%$44 - $51.12
($47.81)
$ 50.085%Add 0.77%11,782,180
SNYThird Avenue Management 2015-03-31 Sold Out -0.012%$44 - $51.12
($47.81)
$ 50.085%Sold Out0
SNYDodge & Cox 2015-03-31 Reduce-0.01%$44 - $51.12
($47.81)
$ 50.085%Reduce 0.55%43,034,073
SNYFirst Eagle Investment 2015-03-31 Sold Out -0.0038%$44 - $51.12
($47.81)
$ 50.085%Sold Out0
SNYCharles Brandes 2015-03-31 Add$44 - $51.12
($47.81)
$ 50.085%Add 0.08%2,573,969
SNYMario Gabelli 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 50.085%Reduce 9.53%4,700
SNYKen Fisher 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 50.085%Reduce 0.21%13,058,095
SNYHOTCHKIS & WILEY 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 50.083%Add 18.16%11,692,693
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 50.083%Add 22.12%2,941,923
SNYCharles Brandes 2014-12-31 Add0.21%$44.4 - $55
($48.49)
$ 50.083%Add 14.36%2,571,795
SNYJames Barrow 2014-12-31 Add0.15%$44.4 - $55
($48.49)
$ 50.083%Add 8.87%30,804,459
SNYDavid Dreman 2014-12-31 Buy $44.4 - $55
($48.41)
$ 50.083%New holding1,102
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-48.28view
Sanofi10% Owner 2015-01-26Buy647,448$95-48.28view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-47.27view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-26.54view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67540.55view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    Dodge & Cox Funds' 2015 Equity Mid-Year Review Aug 19 2015 
    John Buckingham Buys 10 New Stakes in Second Quarter Aug 14 2015 
    Ariel Capital Advisors bought Sanofi and Priceline in Q2 2015 Jul 31 2015 
    Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
    Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
    Mt Stocks Apr 19 2015 
    Scottrade Mar 22 2015 
    Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 

    More From Other Websites
    Cholesterol drug wars: Amgen Aug 27 2015
    MannKind And Afrezza: Can The Drug Cure The Company? Aug 26 2015
    Dividend cuts for big oil? Aug 20 2015
    Cholesterol war heats up Aug 20 2015
    Relypsa Enters Two-Year Detailing Agreement With Sanofi in the United States Aug 18 2015
    Wait, There are Still Cheap Pharma Stocks? Aug 18 2015
    Research and Markets: Investigation Report on China's Polyene Phosphatidyl Choline Market 2010-2019 Aug 17 2015
    John Buckingham Buys 10 New Stakes in Second Quarter Aug 14 2015
    VCEL: Solid Q2 Financial Results. Expect Continued Revenue Growth in 2H 2015 Aug 14 2015
    Payers Set To Play Hardball On PCSK9 Pricing: RBC Aug 13 2015
    The Chemical Works of Gedeon Richter Plc Earnings Q2*, 2015 Aug 13 2015
    Immune Design's Q2 Loss Narrows Y/Y, Focus on Pipeline Aug 13 2015
    Make Room for Exelixis in Your Portfolio Aug 12 2015
    Takeda Pharmaceutical Co., Ltd. Earnings Q2*, 2015 Aug 12 2015
    Dr. Reddy’s Laboratories Ltd. Earnings Q2*, 2015 Aug 12 2015
    Regeneron Pharmaceuticals, Oshkosh, Amgen and Caterpillar highlighted as Zacks Bull and Bear of the... Aug 12 2015
    Industrial Production in France Dipped in June, yet EWQ up 1.11% Aug 11 2015
    MannKind (MNKD) Reports Narrower-than-Expected Q2 Loss - Analyst Blog Aug 11 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK